Mental and Behavioral Health

Pharmacists face alarming burnout rates, but hobbies—from horses to sports—can help protect mental health and keep patient care safer.

A study finds prior-authorization bans do not boost buprenorphine retention for patients on private insurance.

GLP-1 diabetes drugs show promise in cutting addiction risk and overdose deaths, hinting at new options for substance use disorder prevention and care.

The FDA approves Bysanti (milsaperidone) for schizophrenia and bipolar I disorder, leveraging iloperidone bioequivalence, with key metabolic monitoring needs.

As pharmacists continue to take on greater clinical roles, the growing need to address mental health concerns is reaching a boiling point.

Lumateperone shows promising remission rates for major depressive disorder, offering hope for sustained relief in adults when combined with antidepressants.

Pharmacists play a vital role in integrating diabetes and depression care, enhancing patient outcomes through screening, individualized treatment, and collaborative approaches.

Researchers want to bolster evidence regarding the known link between maternal mental health and childhood nutritional status.

Tardive dyskinesia presents significant challenges for patients, but new FDA-approved treatments offer hope for improved management and quality of life.

FDA approves lumateperone as an adjunct therapy for major depressive disorder, offering new treatment options for this indication.

Research reveals no significant disparities in cardiovascular disease incidence linked to mental disorders after the COVID-19 pandemic.

The FDA approves Uzedy, a long-acting risperidone injection, enhancing treatment options for adults with bipolar I disorder and addressing unmet needs.

In pharmacies in predominantly Black and Latino neighborhoods, only 18% and 17% were likely to carry buprenorphine compared with White neighborhoods.

Pharmacies face significant challenges in filling buprenorphine prescriptions for telemedicine patients, impacting opioid use disorder treatment access and patient satisfaction.

Researchers explored the effectiveness of pharmacist-led interventions for improving medication adherence among a group of patients with chronic diseases.

Offering a glimpse into how social isolation and loneliness impact health outcomes, researchers explored how pharmacists promote social health care among their patients.

The FDA also recommended a scheduling action for 7-hydroxymitragynine (7-OH), with data showing the drug binds to opioid receptors.

Community pharmacists embrace mental health interventions to combat depression and anxiety in long-term condition patients, enhancing overall care and accessibility.

The risk of untreated depression for pregnant women can cause adverse outcomes, which can include relapse in mood symptoms, suicide, and overdose death.

Older adults with insomnia face heightened depression risks during inflammation, highlighting the need for targeted monitoring and treatment strategies.

Researchers examined the factors attributed to self-reported resilience among diverse and community-dwelling adults during the COVID-19 pandemic.

Pharmacists play a role in educating patients as well as making them feel more comfortable when utilizing opioid use treatment.

Thimerosal is a mercury-containing compound that has been widely used as a preservative in some biological and drug products since the 1930s.

In 2023, drug overdose deaths sustained declines, but there are still disparities that need to be addressed to continue to decrease these numbers.

PET and autopsy assays suggest that Alzheimer disease (AD) and non-AD tau pathologies could be the underlying cause of some late-life mood disorders.